Article

Biennial eye exam suggested for diabetics

New York-Receiving an eye screening every 2 years instead of annually is just as effective for people with diabetes who have no signs of retinal disease when it comes to not delaying treatment, according to Icelandic researchers in the December issue of the British Journal of Ophthalmology.

New York-Receiving an eye screening every 2 years instead of annually is just as effective for people with diabetes who have no signs of retinal disease when it comes to not delaying treatment, according to Icelandic researchers in the December issue of the British Journal of Ophthalmology.

"Diabetic blindness is one of the most common causes of blindness in the world," investigator Einar Stefansson, MD, PhD, told Reuters Health, "and in many countries, for example, [in the] United Kingdom, the most common cause for working-age people going blind."

"The prevalence of diabetic blindness has been and can be decreased by 50 to 80% with the public health approach," he said. "Thousands of people around the world are blind because of inadequate public health organization in eye care."

While observing 296 patients with diabetes and no retinopathy during 1994 and 1995, who following this had biennial screenings for 10 years, 172 patients did not develop diabetic retinopathy.

Those who had developed macular edema or proliferative retinopathy went to an annual screening program before sight-threatening retinopathy developed.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times) ASCRS 2025: Mark Lobanoff, MD, on making the move to office-based surgery
Barsha Lal, PhD, discusses the way low dose atropine affects accommodative amplitude and dynamics at the 2025 ARVO meeting
(Image credit: Ophthalmology Times) NeuroOp Guru: When eye findings should prompt neuroimaging in suspected neuro-Behcet disease
At the Association for Research in Vision and Ophthalmology (ARVO) meeting, Katherine Talcott, MD, a retina specialist at Cleveland Clinic, shared her findings on EYP-1901 (EyePoint Pharmaceuticals) in the phase 2 DAVIO study.
Dr. Jogin Desai, founder of Eyestem Research, discusses his research at the Association for Research in Vision and Ophthalmology.
(Image credit: Ophthalmology Times) ASCRS 2025: Michael Rivers, MD, shares his takeaways as a panelist at the inaugural SightLine event
(Image credit: Ophthalmology Times) ASCRS 2025: Karl Stonecipher, MD, on LASIK outcomes using an aspheric excimer laser for high myopia
John Tan talks about an emergency triage framework for retinal artery occlusion at the 2025 Association for Research in Vision and Ophthalmology (ARVO) meeting.
Dr Robert Maloney at the 2025 Controversies in Modern Eye Care meeting
Wendy Lee, MD, MS, at Controversies in Modern Eye Care 2025.
© 2025 MJH Life Sciences

All rights reserved.